{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-066571","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.142913+00:00","generated_at":"2026-06-01T07:21:29.375325+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development","bullets":["FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.","Nomlabofusp is one of three CDER programs selected; BLA submission target remains 2H 2025.","START program offers enhanced ad-hoc FDA communication to expedite pivotal studies and BLA preparation.","Interim data from ongoing open-label extension study expected in Q4 2024.","Nomlabofusp aims to increase frataxin levels, addressing root cause of Friedreich's ataxia."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-066571","json":"https://secwatch.observer/filing/0000950170-24-066571.json","markdown":"https://secwatch.observer/filing/0000950170-24-066571.md","text":"https://secwatch.observer/filing/0000950170-24-066571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/0000950170-24-066571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/lrmr-20240530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:21:29.375325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}